Time filter

Source Type

Ling Y.,Soochow University of China | Chen J.,Jiangsu Cancer Hospital | Tao M.,Soochow University of China | Chu X.,Nanjing General Hospital of Nanjing Military Command | Zhang X.,Northern Jiangsu Peoples Hospital
Journal of Thoracic Disease | Year: 2012

Objective: To observe the short-term effect and adverse reaction of Nimotuzumab in combination with chemotherapy on advanced esophageal squamous cell carcinoma (ESCC). Method: 19 patients were treated with the following protocol: Nimotuzumab 400mg/time/week in the 1st week, 200mg/time/week from the 2nd to 8th week, intravenous drip (IVD); Cisplatin 80mg/m2, IVD, 4 weeks a cycle and repeated again; 5-FU 750mg/m2, continuous 24-hours pump-in × 5 days, 4 weeks a cycle and repeated again. Result: 16 of all 19 patients can be evaluated. After treatment, RP is 42.1% (95% CI, 19.9-64.3%) and DCR is 68.4%; the main side effects include arrest of bone marrow, gastrointestinal reactions, asthenia, etc. Conclusion: Nimotuzumab in combination with cisplatin/5-FU regimens in patients with advanced ESCC is safe and effective, which deserves a further expanded sample research. © Pioneer Bioscience Publishing Company.

Gu X.-H.,Peoples Care | Xu J.,Northern Jiangsu Peoples Hospital
Chinese Journal of Contemporary Neurology and Neurosurgery | Year: 2015

There is no epidemiological data of frontotemporal dementia (FTD) in China. The application of updated diagnostic criteria, publishing of frontotemporal lobar degeneration (FTLD) consensus in China, development of multimodal imaging and biomarkers promote the clinical understanding on behavioral variant frontotemporal dementia (bvFTD). There is still no drugs treating FTD approved by U.S. Food and Drug Administration (FDA). Multidisciplinary intervention may delay the progression of bvFTD. Copyright © 2015 by the Editorial Board of Chinese Journal of Contemporary Neurology and Neurosurgery.

Xiao Q.,Northern Jiangsu Peoples Hospital
Zhonghua nan ke xue = National journal of andrology | Year: 2011

To investigate the expressions of the FHIT and PTEN genes and their significance in prostate cancer. The expressions of FHIT and PTEN were detected in 85 cases of prostate cancer and 30 cases of benign prostatic nodular hyperplasia by immunohistochemistry of PV-6000. The positive expression rates of FHIT and PTEN were 34.1% and 42.4% in prostate cancer, significantly lower than 96.7% and 90.0% in benign prostatic nodular hyperplasia (P <0.01). Statistically significant differences were found in the positive expression rates of FHIT and PTEN among different Gleason grades, 44.4% and 55.6% in well differentiated, 38.9% and 44.4% in moderately differentiated, and 25.0% and 37.5% in lowly differentiated prostate cancer (P <0.05). But the expression of FHIT. FHIT and PTEN may play a certain role in the was not correlated with that of PTEN in the prostate cancer tissue (P >0.05). development, progression and infiltration of prostate cancer.

Cunsheng W.,Nanjing Medical University | Jun X.,Northern Jiangsu Peoples Hospital
National Medical Journal of China | Year: 2014

Objective: To explore the characteristics of cognitive impairment and correlation analysis in patients with chronic renal failure (CRF).Methods: The Addenbrooke's cognitive examination revised (ACE-R) scale was used to evaluate the cognitive function for 101 cases of chronic renal failure patients (group CRF) receiving outpatient and inpatient treatments and selected 30 individuals with normal renal function as normal controls (group NC) for cross-sectional analysis. T test, receiver operating characteristic (ROC) curve and other statistical methods were adopted for comparing differences.Results: (1) Compared with group NC (83. 4 ±6. 5), group CRF(71. 9 ± 17. 6) showed significantly statistical difference on Addenbrooke's cognitive examination revised (ACE-R) scale scores (P < 0. 01); (2) compared with normal controls, the patients with CRF had significantly statistical difference on the scores of visual spatial ability (11. 5 ± 3. 2,14. 0 ± 3. 0 respectively), language fluency (7. 0 ± 2. 6, 8.7 ±1.9) (P<0.01) and memory (18. 1 ±7. 0,21. 5 ±3. 6 respectively) (P<0.05); (3) the cognitive function of patients with CRF were significantly positive correlated with glomerular filtration rate (GFR) (r = 0. 614, P <0. 01) and negatively correlated with the duration of illness (r - -0. 492, P <0. 01); (4) From ROC curve and the area under curve (AUC), ACE-R scale (AUC =0. 680) showed a higher sensitivity than mini-mental state examination scale (AUC = 0. 576) in assessing cognitive function in patients with CRF (P <0. 01).Conclusion: (1) Under similar basic conditions of age, level of education and background, CRF patients showed significant damage overall cognitive function, cognitive impairment in visual spatial ability, executive function, long-term memory and logical judgment ability was particularly impaired. Immediate and delayed memory, attention, orientation and language ability also manifested different degrees of decline; (2) the severity of cognitive impairment in patients with CFR was closely related with the level of GFR; (3) the ACE-R scale showed a higher sensitivity than mini-mental state examination scale in assessing cognitive function in patients with CRF.

Hu B.-S.,Chinese PLA General Hospital | Zhao G.,Xian Jiaotong University | Yu H.-F.,Northern Jiangsu Peoples Hospital | Chen K.,Northern Jiangsu Peoples Hospital | And 2 more authors.
Tumor Biology | Year: 2013

The aim of this study was to evaluate the association between activating enhancer binding protein 4 (AP-4) tissue expression and patient prognosis in hepatocellular carcinoma (HCC). The levels of AP-4 mRNA and protein in tumor and para-tumor tissue were evaluated in 30 HCC cases by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot. Additionally, AP-4 protein expression in 112 HCC was analyzed by immunohistochemistry. The correlation of AP-4 expression and patients' clinicopathological parameters was evaluated. Survival analysis was performed using the Kaplan-Meier method and Cox's proportional hazards model. By RT-PCR and Western blot, the levels of AP-4 mRNA and protein were significantly higher in HCC, compared to that in para-tumor tissue (p < 0.001). Immunohistochemical staining revealed that AP-4 was highly expressed in 53.6 % of the HCC patients. The AP-4 expression level was closely associated with serum alpha fetoprotein elevation, tumor size, histological differentiation, tumor recurrence, tumor metastasis, and tumor stage. Kaplan-Meier survival analysis showed that a high expression level of AP-4 resulted in a significantly poor prognosis of HCC patients. Multivariate analysis revealed that AP-4 expression level was an independent prognostic parameter for the overall survival rate of HCC patients. These findings provide evidence that a high expression level of AP-4 serves as a biomarker for poor prognosis for HCC. Thus, we speculate that AP-4 may be a potential target of antiangiogenic therapy for HCC. © 2012 International Society of Oncology and BioMarkers (ISOBM).

Discover hidden collaborations